HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Psychological Sexual Dysfunctions (Sexual Arousal Disorder)

Subscribe to New Research on Psychological Sexual Dysfunctions

Disturbances in sexual desire and the psychophysiologic changes that characterize the sexual response cycle and cause marked distress and interpersonal difficulty. (APA, DSM-IV, 1994)

Also Known As:

Sexual Arousal Disorder; Frigidity; Psychosexual Disorder; Hypoactive Sexual Desire Disorder; Orgasmic Disorders; Orgasmic Disorder; Sexual Aversion Disorder; Sexual Dysfunctions, Psychological; Arousal Disorders, Sexual; Aversion Disorders, Sexual; Disorder, Psychosexual; Disorders, Orgasmic; Disorders, Psychosexual; Disorders, Sexual Arousal; Disorders, Sexual Aversion; Dysfunction, Psychological Sexual; Dysfunction, Psychosexual; Dysfunctions, Psychological Sexual; Dysfunctions, Psychosexual; Psychological Sexual Dysfunction; Psychosexual Dysfunction; Sexual Arousal Disorders; Sexual Aversion Disorders; Sexual Dysfunction, Psychological; Psychosexual Disorders; Psychosexual Dysfunctions

Networked: 195 relevant articles (27 outcomes, 54 trials/studies)

Relationship Network

Disease Context: Research Results

Mental Disorders: 2989
- Sexual and Gender Disorders
  - Psychological Sexual Dysfunctions: 195

Related Diseases

1.	Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
2.	Breast Neoplasms (Breast Cancer)
3.	Psychological Sexual Dysfunctions (Sexual Arousal Disorder)
4.	Erectile Dysfunction
5.	Dyspareunia

Experts

1.	Davis, Susan R: 8 articles (07/2014 - 07/2004)
2.	Simon, James A: 7 articles (11/2015 - 07/2005)
3.	Rodenberg, Cynthia: 7 articles (01/2009 - 07/2005)
4.	Buch, Akshay: 6 articles (07/2009 - 05/2005)
5.	Sommer, Bernd: 5 articles (12/2013 - 06/2010)
6.	Katz, Molly: 5 articles (07/2013 - 07/2005)
7.	Allers, Kelly A: 5 articles (05/2013 - 06/2010)
8.	Kingsberg, Sheryl A: 4 articles (06/2014 - 05/2005)
9.	Sand, Michael: 4 articles (06/2014 - 10/2011)
10.	Garcia, Miguel: 4 articles (06/2014 - 03/2012)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Psychological Sexual Dysfunctions:

1.	Testosterone (Sustanon)FDA Link 06/01/2010 - "Transdermal testosterone is effective in the treatment of hypoactive sexual desire disorder (HSDD) documented in multiple, well-powered randomized clinical trials with demonstrated high levels of safety. " 03/01/2008 - "Based upon our 1 year follow-up, low-dose testosterone is a safe and effective approach in treating hypoactive sexual desire disorder in a fragile X carrier female, provided the patient is monitored every 3 months for blood counts, lipid profiles, liver functions and free and total testosterone levels." 01/01/2007 - "In particular, the article focuses on testosterone therapy for hypoactive sexual desire disorder (a component of FSD), and the role of the Division of Reproductive and Urologic Products in facilitating the development of safe and effective therapies for this indication." 07/25/2005 - "Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial." 02/01/2010 - "The available clinical evidence supports efficacy of testosterone therapy for the treatment of postmenopausal women with hypoactive sexual desire disorder (HSDD) who have undergone a comprehensive clinical evaluation. "
2.	flibanserin (BIMT 17)IBA 10/01/2010 - "Although these studies were not designed or powered to compare sexual function outcomes, results suggested a potential benefit of flibanserin on sexual function, particularly on female sexual desire, and provided a rationale to evaluate the efficacy of flibanserin as a treatment for female hypoactive sexual desire disorder." 07/01/2013 - "Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial." 04/01/2012 - "Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study." 03/01/2012 - "Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study." 06/01/2014 - "Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial."
3.	sildenafil (Viagra)FDA Link 12/01/2003 - "For women with FSAD without concomitant hypoactive sexual desire disorder (HSDD) sildenafil was associated with significantly greater improvement in 5 of 6 FIEI items compared with placebo (p <0.02). " 10/01/2014 - "angustifolia extract and sildenafil citrate were effective in reduction of the frequency of orgasmic disorder in women." 05/01/2006 - "To verify whether sildenafil is effective in type 1 premenopausal women affected by sexual arousal disorder (SAD). " 12/01/2003 - "Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study." 10/01/2001 - "The goal of this pilot study was to determine safety and efficacy of sildenafil for use in women with sexual arousal disorder (SAD). "
4.	Bupropion (Wellbutrin)FDA LinkGeneric 09/01/2010 - "To compare the efficacy of sustained-release (SR) bupropion to placebo in treating hypoactive sexual desire disorder (HSDD) in ovulating women. " 01/01/1987 - "Sixty female and male outpatients with psychosexual dysfunction (sexual aversion/inhibited sexual desire, inhibited sexual excitement, and/or inhibited orgasm) participated in a comparison of the efficacy of bupropion hydrochloride vs placebo. " 01/01/2012 - "This article describes the results of an independent small-scale trial with the centrally acting agent bupropion for female hypoactive sexual desire disorder. " 09/01/2010 - "A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women." 06/01/2004 - "Premenopausal women meeting operational criteria for idiopathic, acquired, global hypoactive sexual desire disorder were studied in a randomized, double-blind, placebo-controlled, multiple-site escalating dose 112-day trial of bupropion sustained release. "
5.	Estrogens (Estrogen)FDA Link 09/01/2006 - "A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial was conducted in naturally menopausal women with hypoactive sexual desire disorder receiving a stable dose of oral estrogen with or without progestin (N = 549). " 10/01/2007 - "A new female androgen patch has been licensed in Europe for treatment of low libido causing distress (hypoactive sexual desire disorder) in surgically menopaused women on estrogen therapy. " 07/01/2004 - "Systemic estrogen/estrogen progestin therapy alleviates climacteric symptoms but there is no evidence that this therapy specifically improves hypoactive sexual desire disorder (HSDD) in premenopausal or postmenopausal women. " 12/19/2005 - "In phase 3 trials, a testosterone transdermal matrix patch has been shown to be effective in treatment of hypoactive sexual desire disorder in menopausal women on estrogen therapy. " 03/01/2007 - "The transdermal testosterone patch is an effective treatment for hypoactive sexual desire disorder in surgically postmenopausal women receiving concomitant estrogen therapy. "
6.	Carbon MonoxideIBA 01/01/2012 - "However, no studies have examined characteristics of women with clinically diagnosed hypoactive sexual desire disorder (HSDD) that increase the likelihood of co-occurring arousal difficulties. " 07/01/1984 - "70 (60,8%) patients have sexual dysfunction in post infarction as: partner's lack of co-operation 34 (48,6%), premature ejaculation 12 (17,1%), erectile failure 7 (10%), frigidity 6 (8,6%), sexual dissatisfaction 4 (5,7%), retarded ejaculation 2 (2,9%), various disorders 5 (7,1%), 58 (50,4%) partners have sexual dysfunction as: frigidity 22 (37,9%), sexual dissatisfaction 19 (32,8%), partners lack of co-operation 7 (12,1%), erectile failure 3 (5,2%), retarded ejaculation 2 (3,5%), various disorders 5 (8,6%). " 05/01/2014 - "We recommend screening for and treating co-morbid depression, testosterone deficiency and striving for clinical remission to prevent psychosexual dysfunction in male patients with inflammatory bowel disease."
7.	Dehydroepiandrosterone (DHEA)IBA 08/01/2013 - "Data regarding the efficacy of dehydroepiandrosterone (DHEA) in the treatment of hypoactive sexual desire disorder (HSDD) are scarce and inconsistent. " 11/01/2003 - "The use of DHEA therapy may also be discussed in women of any age when a trial of androgen supplementation seems justified because of the existence of an inhibited sexual desire or a sexual arousal disorder associated with documented androgen deficiency. " 08/01/2013 - "The use of dehydroepiandrosterone in the treatment of hypoactive sexual desire disorder: a report of gender differences."
8.	ApomorphineIBA 05/01/2004 - "To verify whether apomorphine SL is effective in premenopausal women affected by arousal disorder with hypoactive sexual desire disorder. " 05/01/2004 - "Placebo-controlled study on efficacy and safety of daily apomorphine SL intake in premenopausal women affected by hypoactive sexual desire disorder and sexual arousal disorder." 04/01/1997 - "A similar pattern of psychosexual disorders has been observed after long-term treatment with levodopa therapy in four male parkinsonian patients treated with apomorphine for severe on-off motor fluctuations. "
9.	gepironeIBA 09/01/2011 - "Gepirone-extended release (ER) is effective in treating hypoactive sexual desire disorder (HSDD), as measured by the percent of females with HSDD that no longer met criteria for HSDD treatment. " 10/01/2011 - "Errata by Fabre et al. in gepirone-ER treatment of hypoactive sexual desire disorder associated with depression in women." 05/01/2011 - "Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women."
10.	Biological Markers (Surrogate Marker)IBA 01/01/2003 - "These MRI techniques may also prove useful as a surrogate end point marker for testing efficacy of future new treatments for women with sexual arousal disorder."

Therapies and Procedures

1.	Ovariectomy (Oophorectomy) 07/01/2012 - "The occurrence of an androgen deficiency syndrome associated with loss of libido and sense of well-being is disputed, but in several randomized controlled trials, transdermal T patches produced a significant improvement in hypoactive sexual desire disorder in postmenopausal women who had bilateral oophorectomy and in some women who had a natural menopause. " 05/01/2005 - "Five hundred thirty-three women with hypoactive sexual desire disorder who had undergone previous hysterectomy and bilateral oophorectomy were enrolled in a 24-week, multicenter, double-blind, placebo-controlled trial. " 06/01/2008 - "Randomized trials have demonstrated an improvement in sexual function with testosterone in postmenopausal women with hypoactive sexual desire disorder, particularly after oophorectomies. " 07/01/1999 - "Three cases of women who had undergone a total abdominal hysterectomy with bilateral oophorectomy with complaints consistent with female hypoactive sexual desire disorder and free testosterone levels of < 2.0 pg/ml are presented. " 05/01/2006 - "Evaluation of the use of testosterone therapy for hypoactive sexual desire disorder (HSDD) after oophorectomy has mostly involved women treated with oral estrogen preparations. "
2.	Meditation 12/01/2015 - "Publications claim efficacy for treatment of hypoactive sexual desire disorder (HSDD) in women with cognitive behavior therapy (CBT) and mindfulness meditation training (MMT). "
3.	Hysterectomy 04/01/2013 - "The aim of this study was to compare the prevalence of hypoactive sexual desire disorder (HSDD) after five different hysterectomy procedures. " 04/01/2013 - "Comparison of prevalence of hypoactive sexual desire disorder (HSDD) in women after five different hysterectomy procedures." 01/28/1978 - "The problem of psychosexual disorders following hysterectomy is reviewed. " 05/01/2005 - "Five hundred thirty-three women with hypoactive sexual desire disorder who had undergone previous hysterectomy and bilateral oophorectomy were enrolled in a 24-week, multicenter, double-blind, placebo-controlled trial. " 01/01/1993 - "To assess the prevalence and severity of psychosexual dysfunction in women treated for cancer of the cervix and vulva by radical vulvectomy, Wertheim's hysterectomy and pelvic exenteration; and to identify the risk factors for sexual morbidity and ways in which it might be reduced. "
4.	Hypnosis (Mesmerism) 03/01/1975 - "Successful treatment of frigidity through hypnosis." 01/20/1974 - "[Hypnosis therapy for the cure of frigidity]." 01/01/1974 - "Hypnosis and frigidity." 01/01/2005 - "A discussion of sexual dysfunction at this end of the continuum and cases of Hypoactive Sexual Desire Disorder and Vaginismus demonstrate the clinical effectiveness of an approach combining hypnosis and ego-state therapy to facilitate healthy adaptive differentiation." 07/01/1971 - "Marital crisis intervention: hypnosis in impotence-frigidity cases."
5.	Contraception (Birth Control) 04/20/1980 - " In many adult women the use of OC (oral contraception) is in serious conflict with their unconscious desire for a child; such conflict is often cause of psychological problems and also of physiological ones, such as frigidity. " 06/01/1989 - " Although these media show prostitution, homosexuality, rape, frigidity, menopause, abortion, infidelity, divorce, and impotence, there is little about birth control, self- control, abstinence, or responsibility. " 01/01/1975 - "Pathological conduct that compromises contraception includes sexual inhibition, frigidity, homosexuality, phobias, obsessions, and hysteria. " 02/01/1991 - " Symptoms after an abortion may include frigidity, vaginismus, dyspareunia, pain, or poor tolerance of contraception desired at the conscious level. " 05/01/2015 - "Specialized training in WH is crucial to educate leaders who can appropriately integrate this multidisciplinary field into academic centers, especially as the demand for providers confident in the areas of contraception, perimenopause/menopause, hormone therapy, osteoporosis, hypoactive sexual desire disorder, medical management of abnormal uterine bleeding, office based care of stress/urge incontinence, and gender-based medicine are increasing popular and highly sought after. "